ESC26: Can Arrowhead pierce Ionis' triglyceride armour?
Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.
ESC26: AZ's relaxin agonist shows promise in heart failure
An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients with heart failure.
FDA clears Takeda, Protagonist's first-in-class PV drug
Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.
ESC26: Cytokinetics' big data reveal for Myqorzo impresses
Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.
Acquisitive Lilly offers $2.88bn for Merida Bio
Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities
2nd World-RNA Based Therapeutics & Vaccines Summit South Kor...
Korea’s Forum to Advance mRNA, CircRNA & saRNA Medicines for Clinical & Commercial Readiness
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel